

References

- Abergel A., Darcha C., Chevallier M., et al:** Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis. *Eur J Gastroenterol Hepatol* 16. 1219-1227. 2004.
- Adams L.A., Bulsara M., Rossi E., et al:** Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. *Clin Chem* 51. (10): 1867-1873. 2005.
- Aguirre D.A., Behling C.A., Alpert E., et al:** Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging. *Radiology* 239. (2): 425-437. 2006.
- Aithal G.P., Haugk B., Das S., et al:** Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? *Aliment Pharmacol Ther* 19. 391-399. 2004.
- Akinc A., Zumbuehl A., Goldberg M., et al:** A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. *Nat Biotechnol* 26. 561-569. 2008.
- Akriviadis E., Botla R., Briggs W., et al:** Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. *Gastroenterology* 119. 1637-1648. 2000.
- Albano E.:** Oxidative mechanisms in the pathogenesis of alcoholic liver disease. *Mol Aspects Med* 29. 9-16. 2008.
- Aleynik S.I., Leo M.A., Ma X., et al:** Polyenylphosphatidylcholine prevents carbon tetrachloride-induced lipid peroxidation while it attenuates liver fibrosis. *J Hepatol* 27. 554-561. 1997.

- Alter MJ.** The epidemiology of hepatitis C in the west. *Semin liver Dis* 1995; 15:5-14.
- Alter MJ:** Epidemiology of hepatitis C. *Eur J Gastroenterol Hepatol* 8 (4): 319-323.1996.
- Angelico M., Cepparulo M., Barlattani A., et al:** Unfavourable effects of colchicine in combination with interferon-alpha in the treatment of chronic hepatitis C. *Aliment Pharmacol Ther* 14. 1459-1467.2000.
- Angulo P., Hui J.M., Marchesini G., et al:** The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. *Hepatology* 45. (4): 846-854. 2007.
- Anonymous:** The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European multicentre study group. *J Hepatol* 17. 227-235.1993.
- Arena U., Vizzutti F., Corti G., et al:** Acute viral hepatitis increases liver stiffness values measured by transient elastography30. *Hepatology* 47. (2): 380-384. 2008.
- Armstrong GL, Wasely A, Simard EP.,et al:**The prevalence of hepatitis C virus infection in the united states, *Annals of internal medicine*.144:705-714.2006
- Armendariz-Borunda J., Islas-Carbajal M.C., Meza-Garcia E., et al:** A pilot study in patients with established advanced liver fibrosis using pirfenidone. *Gut* 55. 1663-1665.2006.
- Arthur M.J.:** Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. *Am J Physiol Gastrointest Liver Physiol* 279. G245-G249. 2000.

- Azuma A., Nukiwa T., Tsuboi E., et al:** Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 171. 1040-1047.2005.
- Bach N., Bodian C., Bodenheimer H., et al:** Methotrexate therapy for primary biliary cirrhosis. *Am J Gastroenterol* 98. 187-193.2003.
- Bach N., Thung S.N., Schaffner F.:** The histologic effects of low-dose methotrexate therapy for primary biliary cirrhosis. *Arch Pathol Lab Med* 122. 342-345.1998.
- Backus LI, Boothroyd DB, Phillips BR, et al.:** Predictors of response of US veterans to treatment for the hepatitis C virus. *Hepatology* 46. (1): 37-47. 2007.
- Bahcecioglu I.H., Koca S.S., Poyrazoglu O.K., et al:** Hepatoprotective effect of Infliximab, an anti-TNF-alpha agent, on carbon tetrachloride-induced hepatic fibrosis. *Inflammation* 31. 215-221. 2008.
- Bataller R & Brenner DA.** Liver fibrosis. *J Clin Invest* 2005; 115: 209-18.
- Bataller R, Gabele E, Parsons CJ, et al.** Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. *Hepatology* 2005;41:1046-55.
- Bataller R., Gabele E., Parsons C.J., et al:** Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. *Hepatology* 41. 1046-1055.2005.
- Bataller R., Sancho-Bru P., Gines P., et al:** Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. *Gastroenterology* 125. 117-125.2003.

- Bedossa P., Dargere D. and Paradis V.:** Sampling variability of liver fibrosis in chronic hepatitis C. *Hepatology* 38. (6): 1449-1457.2003.
- Bedossa P., Dargere D., Paradis V.:** Sampling variability of liver fibrosis in chronic hepatitis C. *Hepatology* 38. 1449-1457.2003.
- Belfort R., Harrison S.A., Brown K., et al:** A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. *N Engl J Med* 355. 2297-2307.2006.
- Beljaars L., Molema G., Schuppan D., et al:** Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor. *J Biol Chem* 275. 12743-12751. 2000.
- Benyon R.C., Iredale J.P., Goddard S., et al:** Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. *Gastroenterology* 110. 821-831.1996.
- Blasco A., Forns X., Carrion J.A., et al:** Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. *Hepatology* 43. (3): 492-499.2006.
- Blomley M., Albrecht T., Cosgrove D., et al:** Stimulated acoustic emission in liver parenchyma with Levovist. *Lancet* 351. (9102): 568.1998.
- Blomley M.J., Albrecht T., Cosgrove D.O., et al:** Improved imaging of liver metastases with stimulated acoustic emission in the late phase of enhancement with the US contrast agent SH U 508A: early experience. *Radiology* 210. (2): 409-416. 1999.
- Blumberg R.S., Chopra S., Ibrahim R., et al:** Primary hepatocellular carcinoma in idiopathic hemochromatosis after reversal of cirrhosis. *Gastroenterology* 95. 1399-1402.1988.

- Bodenheimer , Jr. , Jr.H.C., Schaffner F., Sternlieb I., et al:** A prospective clinical trial of D-penicillamine in the treatment of primary biliary cirrhosis. *Hepatology* 5. 1139-1142.1985.
- Boetticher N.C., Piene C.J., Kwo P., et al:** *Gastroenterology* 134. A765. 2008.
- Boigk G., Stroedter L., Herbst H., et al:** Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. *Hepatology* 26. 643-649.1997.
- Bolkenius U., Hahn D., Gressner A.M., et al:** Glucocorticoids decrease the bioavailability of TGF-beta which leads to a reduced TGF-beta signaling in hepatic stellate cells. *Biochem Biophys Res Commun* 325. (4): 1264-1270. 2004.
- Boulanger Y., Amara M., Lepanto L., et al:** Diffusion-weighted MR imaging of the liver of hepatitis C patients. *NMR Biomed* 16. (3): 132-136. 2003.
- Brok J, Gluud LL and Gluud C:** Ribavirin monotherapy for chronic hepatitis C. *Cochrane Database Syst Rev*. (4): 2009.
- Brown K.E., Poulos J.E., Li L., et al:** Effect of vitamin E supplementation on hepatic fibrogenesis in chronic dietary iron overload. *Am J Physiol* 272. G116-G123.1997.
- Bruix J and Sherman M:** Practice Guidelines Committee and American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. *Hepatology* 42. (5): 1208-1236.2005.
- Bruno S, Stroffolini T, Colombo M, Italian Association of the Study of the Liver Disease, et al:** Sustained virological response to interferon-alpha is associated with improved outcome in

- HCV-related cirrhosis: a retrospective study. Hepatology 45. (3): 579-587.2007.
- Buck M., Chojkier M.:** A ribosomal S-6 Kinase-mediated signal to C/EBP-beta is critical for the development of liver fibrosis. PLoS ONE 2. e1372.2007.
- Cadranel J.F., Rufat P., Degos F.:** Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the study of the liver (AFEFL). Hepatology 32. (3): 477-481.2000.
- Cales P., Oberti F., Michalak S., et al:** A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 42. (6): 1373-1381. 2005.
- Caligiuri A., Glaser S., Rodgers R.E., et al:** Endothelin-1 inhibits secretin-stimulated ductal secretion by interacting with ETA receptors on large cholangiocytes. Am J Physiol 275. G835-G846.1998.
- Callewaert N., Van Vlierberghe H., Van Hecke A., et al:** Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 10. 429-434.2004.
- Callewaert N., Van Vlierberghe H., Van Hecke A., et al:** Noninvasive diagnosis of liver cirrhosis using DNA sequence-based total serum protein glycomics. Nat Med 10. (4): 429-434.2004.
- Carrion J.A., Navasa M., Bosch J., et al:** Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 12. (12): 1791-1798.2006.
- Castera L., Foucher J., Bertet J., et al:** FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases. Hepatology 43. 373-374.2006.

- Castera L., Vergniol J., Foucher J., et al:** Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. *Gastroenterology* 128. (2): 343-350.2005.
- Centers for Disease Control and Prevention:** Reference for interpretation of hepatitis C virus (HCV) test results. Accessed March 5, 2009.
- Chang P.E., Lui H.F., Chau Y.P., et al:** Prospective evaluation of transient elastography for the diagnosis of hepatic fibrosis in Asians: comparison with liver biopsy and aspartate transaminase platelet ratio index. *Aliment Pharmacol Ther* 28. (1): 51-61. 2008.
- Chevallier M., Guerret S., Chossegros P., et al:** A histological semiquantitative scoring system for evaluation of hepatic C fibrosis in needle liver biopsy specimens: comparison with morphometric C studies. *Hepatology* 20. 349-355.1994.
- Cholongitas E and Papatheodoridis GV:** Review article: novel therapeutic options for chronic hepatitis C. *Aliment Pharmacol Ther* 27. (10): 866-884.2008.
- Chou R, Clark EC, Helfand M, U.S.:** Preventive Services Task Force: Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med* 140. (6): 465-479.2004.
- Cobbold J.F., Taylor-Robinson S.D.:** Transient elastography in acute hepatitis: all that's stiff is not fibrosis. *Hepatology* 47. (2): 370-372. 2008.
- Coco B., Oliveri F., Maina A.M., et al:** Transient elastography: a new surrogate marker of liver fibrosis influenced by major

changes of transaminases. *J Viral Hepat* 14. (5): 360-369. 2007.

Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C, HEPATITIS Group: Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. *J Viral Hepat* 8. (2): 87-95. 2001.

Colli A., Fraquelli M., Andreoletti M., et al: Severe liver fibrosis or cirrhosis: accuracy of US for detection—analysis of 300 cases. *Radiology* 227. 89-94.2003.

Colmenero J, Debernardi-Venon W., Martini S., et al: AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. *J Hepatol* 46. 1026-1033.2009.

Combes B., Carithers, Jr., Jr.R.L., Maddrey W.C., et al: A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. *Hepatology* 22. 759-766.1995.

Corpechot C., Barbu V., Wendum D., et al: Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. *Hepatology* 35. 1010-1021. 2002.

Czaja M.J., Weiner F.R., Eghbali M., et al: Differential effects of gamma-interferon on collagen and fibronectin gene expression. *J Biol Chem* 262. 13348-13351.1987.

Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of the hepatitis C virus(HCV)- infected persons in the united states :A multiple cohort model of HCV prevalence and Diseases progression .*Gastroenterology* 2009.

- De B.K., Bandyopadhyay K., Das T.K., et al:** Portal pressure response to losartan compared with propranolol in patients with cirrhosis. *Am J Gastroenterol* 98. 1371-1376.2003.
- Debernardi-Venon W., Martini S., Biasi F., et al:** AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. *J Hepatol* 46. 1026-1033.2007.
- Deeks J.:** Evaluations of diagnostic and screening tests. In: Egger M., Smith G.D., Altman D.G., ed. *Systematic reviews in health care*, BMJUK 2006.
- Degott C., Zafrani E.S., Callard P., et al:** Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. *Hepatology* 29. 1007-1012.1999.
- Di Sario A., Bendia E., Macarri G., et al:** The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2. *Dig Liver Dis* 36. 744-751.2004.
- Di Sario A., Bendia E., Svegliati Baroni G., et al:** Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. *J Hepatol* 37. 584-591.2002.
- Dickson E.R., Fleming T.R., Wiesner R.H., et al:** Trial of penicillamine in advanced primary biliary cirrhosis. *N Engl J Med* 312. 1011-1015.1985.
- Dienstag J.L., McHutchison J.G.:** American Gastroenterological Association technical review on the management of hepatitis C. *Gastroenterology* 130. 231-264.2006.

- Distributions of hepatitis C genotypes from Epidemiology of Infectious Diseases***, Johns Hopkins Bloomberg School of Public Health Baltimore, Md.2007. Accessed March 26, 2009.
- Donahue JG, Muñoz A, Ness PM, et al***: The declining risk of posttransfusion hepatitis C virus infection. N Engl J Med 327. (6): 369-373.1992.
- Douglas W.W., Ryu J.H., Swensen S.J., et al***: Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group. Am J Respir Crit Care Med 158. 220-225.1998.
- Douglass A., Wallace K., Parr R., et al***: Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury. J Hepatol 49. 88-98.2008.
- Du S.L., Pan H., Lu W.Y., et al***: Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats. J Pharmacol Exp Ther 322. 560-568.2007.
- Dufour J.F., DeLellis R., Kaplan M.M.***: Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 127. 981-985. 1997.
- Eray Kara' , Teoman Coşkun, Yavuz Kaya., et al.*** Effects of silymarin and pentoxifylline on matrix metalloproteinase-1 and -2 expression and apoptosis in experimental hepatic fibrosis . current therapeutic research (9) 488-502 .2009
- Ekstedt M., Franzen L.E., Mathiesen U.L., et al***: Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44. 865-873.2006.

- El-Serag HB and Mason AC:** Rising incidence of hepatocellular carcinoma in the United States. *N Engl J Med* 340. (10): 745-750. 1999.
- El-Serag HB:** Hepatocellular carcinoma: recent trends in the United States. *Gastroenterology* 127. (5 suppl 1): S27-S34.2004.
- Emonard H., Grimaud J.A.:** Active and latent collagenase activity during reversal of hepatic fibrosis in murine schistosomiasis. *Hepatology* 10. 77-83.1989.
- Ferenci P., Dragosics B., Dittrich H., et al:** Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. *J Hepatol* 9. 105-113.1989.
- Fiorucci S., Antonelli E., Rizzo G., et al:** The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. *Gastroenterology* 127. 1497-1512.2004.
- Forns X., Ampurdanes S., Llovet J.M., et al:** Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. *Hepatology* 36. (4 Pt 1): 986-992.2002.
- Foucher J., Castera L., Bernard P.H., et al:** Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations⁵. *Eur J Gastroenterol Hepatol* 18. (4): 411-412. 2006.
- Fraquelli M., Rigamonti C., Casazza G., et al:** Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. *Gut* 56. 968-973.2007.
- Fraquelli M., Rigamonti C., Casazza G., et al:** Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. *Gut* 56. (7): 968-973. 2007.

- Fried MW, Shiffman ML, Reddy KR, et al:** Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 347. (13): 975-982.2002.
- Friedman S.L., Rockey D.C., Bissell D.M.:** Hepatic fibrosis 2006: report of the Third AASLD Single Topic Conference. *Hepatology* 45. 242-249.2007.
- Friedman SL:** Liver fibrosis - from bench to bedside. *J Hepatol* 2003; 38(Suppl. 1): S38-S53
- Friedrich-Rust M, Ong MF, Sarrazin C., et al:** performance of transient elastography for the staging of liver fibrosis: ameta-analysis. *Gastroenterology* 134(4):960-974. 2008.z
- Garcia L., Hernandez I., Sandoval A., et al:** Pirfenidone effectively reverses experimental liver fibrosis. *J Hepatol* 37. 797-805.2002.
- Garcia-Banuelos J., Siller-Lopez F., Miranda A., et al:** Cirrhotic rat livers with extensive fibrosis can be safely transduced with clinical-grade adenoviral vectors. Evidence of cirrhosis reversion. *Gene Ther* 9. 127-134.2002.
- Gebo K.A., Herlong H.F., Torbenson M.S., et al:** Role of liver biopsy in management of chronic hepatitis C: a systematic review. *Hepatology* 36. (5 Suppl 1): S161-S172. 2002.
- George J., Roulot D., Kotliansky V.E., et al:** In vivo inhibition of rat stellate cell activation by soluble TGF beta type II receptor: a potential new therapy for hepatic fibrosis. *Proc Nat Acad Sci U S A* 96. 12719-12724.1999.
- Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases:** Diagnosis, management, and treatment of hepatitis C: an update. *Hepatology* 49. (4): 1335-1374. 2009.

- Girometti R., Furlan A., Bazzocchi M., et al:** Diffusion-weighted MRI in evaluating liver fibrosis: a feasibility study in cirrhotic patients. *Radiol Med (Torino)* 112. (3): 394-408. 2007.
- Gomez-Dominguez E., Mendoza J., Rubio S., et al:** Transient elastography: a valid alternative to biopsy in patients with chronic liver disease. *Aliment Pharmacol Ther* 24. (3): 513-518.2006.
- González V, Martró E, Folch C, et al:** Detection of hepatitis C virus antibodies in oral fluid specimens for prevalence studies. *Eur J Clin Microbiol Infect Dis* 27. (2): 121-126. 2008.
- Gonzalez-Abraldes J., Albillos A., Banares R., et al:** Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. *Gastroenterology* 121. 382-388.2001.
- Gonzalo T., Beljaars L., van de Bovenkamp M., et al:** Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells. *J Pharmacol Exp Ther* 321. 856-865.2007.
- Goulis J., Leandro G., Burroughs A.K.:** Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. *Lancet* 354. 1053-1060.1999.
- Guha I.N., Parkes J., Roderick P., et al:** Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. *Hepatology* 47 (2): 455-460. 2008.
- Guha I.N., Parkes J., Roderick P.R., et al:** Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. *Gut* 55. (11): 1650-1660. 2006.

- Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al:** Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. *N Engl J Med* 348. 800-807.2003.
- Hagens W.I., Beljaars L., Mann D.A., et al:** Cellular targeting of the apoptosis-inducing compound gliotoxin to fibrotic rat livers. *J Pharmacol Exp Ther* 324. 902-910.2008.
- Hammel P., Couvelard A., O'Toole D., et al:** Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. *N Engl J Med* 344. 418-423.2001.
- Hasegawa T., Yoneda M., Nakamura K., et al:** Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. *Aliment Pharmacol Ther* 15. 1667-1672.2001.
- Hazra S., Xiong S., Wang J., et al:** Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. *J Biol Chem* 279. 11392-11401.2004.
- Hendrickse M.T., Rigney E., Giaffer M.H., et al:** Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. *Gastroenterology* 117. 400-407.1999.
- Hezode C., Roudot-Thoraval F., Nguyen S., et al:** Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. *Hepatology* 42. 63-71.2005.
- Hirose A., Ono M., Saibara T., et al:** Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. *Hepatology* 45. 1375-1381.2007.

- Hoofnagle JH and Seeff LB:** Peginterferon and ribavirin for chronic hepatitis C. *N Engl J Med* 355. (23): 2444-2451.2006.
- Houglum K., Venkataramani A., Lyche K., et al:** A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. *Gastroenterology* 113. 1069-1073.1997.
- Huang H., Shiffman M.L., Cheung R.C., et al:** Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. *Gastroenterology* 130. (6): 1679-1687. 2006.
- Hui A.Y., Chan H.L., Wong V.W., et al:** Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. *Am J Gastroenterol* 100. (3): 616-623. 2005.
- Hung CH, Lee CM, Lu SN, et al:** Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. *J Viral Hepat* 13. (6): 409-414.2006.
- Huwart L., Sempoux C., Salameh N., et al:** Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index. *Radiology* 245. (2): 458-466. 2007.
- Iijima H., Moriyasu F., Tsuchiya K., et al:** Decrease in accumulation of ultrasound contrast microbubbles in non-alcoholic steatohepatitis. *Hepatol Res* 37. (9): 722-730. 2007.
- Imbert-Bismut F., Ratziu V., Pieroni L., et al:** Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. *Lancet* 357. 1069-1075.2001.

- Imbert-Bismut F., Ratziu V., Pieroni L., et al:** Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. *Lancet* 357. (9262): 1069-1075.2001.
- Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. *Hepatology* 20. (1 Pt 1): 15-20.1994.
- Isaka Y., Brees D.K., Ikegaya K., et al:** Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. *Nat Med* 2. 418-423.1996.
- Issa R., Williams E., Trim N., et al:** Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. *Gut* 48. 548-557.2001.
- Jackop BP, Jia J.D., Bauer M., et al:** Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1. *J Hepatol* 35. 392-398.2001.
- Jacquemin E., Hermans D., Myara A., et al:** Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. *Hepatology* 25. 519-523.1997.
- Jaeckel E, Cornberg M and Wedemeyer H:** German Acute Hepatitis C Therapy Group, et al: Treatment of acute hepatitis C with interferon alfa-2b. *N Engl J Med* 345. (20): 1452-1457.2001.
- Jarnagin W.R., Rockey D.C., Koteliansky V.E., et al:** Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. *J Cell Biol* 127. 2037-2048.1994.

- Jean-Francois J. Dufour, MD, and Marshall M. Kaplan, MD:** University of Bern, Switzerland, and Tufts University School of Medicine, Boston, Mass, 2005.
- Jia J.D., Bauer M., Cho J.J., et al:** Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1. *J Hepatol* 35. 392-398.2001.
- Jin H., Yamamoto N., Uchida K., et al:** Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet. *Biochem Biophys Res Commun* 364. 801-807.2007.
- Jou JH and Muir AJ:** In the clinic. Hepatitis C. *Ann Intern Med* 148 (11): ITC6-1.2008.
- Julien B., Grenard P., Teixeira-Clerc F., et al:** Antifibrogenic role of the cannabinoid receptor CB2 in the liver. *Gastroenterology* 128. 742-755. 2005.
- Kaplan M.M., Alling D.W., Zimmerman H.J., et al:** A prospective trial of colchicine for primary biliary cirrhosis. *N Engl J Med* 315. 1448-1454.1986.
- Kaplan M.M., Cheng S., Price L.L., et al:** A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results. *Hepatology* 39. 915-923.2004.
- Kaplan M.M., DeLellis R.A., Wolfe H.J.:** Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment. *Ann Intern Med* 126. 682-688.1997.
- Kaul V, FriedenberG FK, Braitman LE, et al.** Development and validation of a model to diagnose cirrhosis in patients with hepatitis C. *Am J Gastroenterol* 2002;97(10):2623-8.

- Kaul V., Friedenberg F.K., Braitman L.E., et al:** Development and validation of a model to diagnose cirrhosis in patients with hepatitis C. *Am J Gastroenterol* 97. (10): 2623-2628. 2002.
- Kaur S, Rybicki L, Bacon BR, Gollan JL, Rustgi VK, Carey WD:** Performance characteristics and results of a large-scale screening program for viral hepatitis and risk factors associated with exposure to viral hepatitis B and C: results of the National Hepatitis Screening Survey. National Hepatitis Surveillance Group. *Hepatology* 24. (5): 979-986.1996.
- Kershenobich D., Vargas F., Garcia-Tsao G., et al:** Colchicine in the treatment of cirrhosis of the liver. *N Engl J Med* 318. 1709-1713.1988.
- Khimji A.K., Shao R., Rockey D.C.:** Divergent transforming growth factor-beta signaling in hepatic stellate cells after liver injury: functional effects on ECE-1 regulation. *Am J Pathol* 173. 716-727. 2008.
- Kinnman N., Francoz C., Barbu V., et al:** The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. *Lab Invest* 83. 163-173.2003.
- Kisseleva T., Uchinami H., Feirt N., et al:** Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. *J Hepatol* 45. 429-438.2006.
- Knodell R.G., Ishak K.G., Black W.C., et al:** Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. *Hepatology* 1. 431-435.1981.

- Koca S.S., Bahcecioglu I.H., Poyrazoglu O.K., et al:** The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. *Inflammation* 31. 91-98.2008.
- Koff RS and Muir A:** Hepatitis C. PIER, American College of Physicians Philadelphia, Pa. 2008.
- Lai C.L., Chien R.N., Leung N.W., et al:** A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. [see comments]*N Engl J Med* 339. 61-68.1998.
- Leroy V., Hilleret M.N., Sturm N., et al:** Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. *J Hepatol* 46. (5): 775-782.2007.
- Lieber C.S., Leo M.A., Cao Q., et al:** Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. *J Clin Gastroenterol* 37. 336-339.2003.
- Lieber C.S., Weiss D.G., Groszmann R., et al:** II. Veterans Affairs Cooperative Study of Polyenylphosphatidylcholine in alcoholic liver disease. *Alcohol Clin Exp Res* 27. 1765-1772.2003.
- Lieber C.S., Weiss D.G., Morgan T.R., et al:** Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis. *Am J Gastroenterol* 101. (7): 1500-1508.2006.
- Lieber CS, Leo MA, Cao Q, et al.** Silymarin retards the progression of alcoholinduced hepatic fibrosis in baboons. *J Clin Gastroenterol* 2003; 37: 336-9.
- Lim A.K., Patel N., Hamilton G., et al:** The relationship of in vivo ³¹P MR spectroscopy to histology in chronic hepatitis C. *Hepatology* 37. (4): 788-794.2003.

- Lim A.K., Taylor-Robinson S.D., Patel N., et al:** Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. *Gut* 54. (1): 128-133. 2005.
- Lindblad A., Glaumann H., Strandvik B.:** A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. *Hepatology* 27. 166-174.1998.
- Lindor K.D., Kowdley K.V., Heathcote E.J., et al:** Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. *Hepatology* 39. 770-778.2004.
- Liu H., Drew P., Gaugler A.C., et al:** Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway. *Am J Transplant* 5. 1256-1263.2005.
- Liu Y., Binz J., Numerick M.J., et al:** Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. *J Clin Invest* 112. 1678-1687.2003.
- Lu S.C., Tsukamoto H., Mato J.M.:** Role of abnormal methionine metabolism in alcoholic liver injury. *Alcohol* 27. 155-162.2002.
- Luk J.M., Wang X., Liu P., et al:** Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation. *Liver Int* 27. 879-890.2007.
- Luk J.M., Zhang Q.S., Lee N.P., et al:** Hepatic stellate cell-targeted delivery of M6P-HSA-glycyrrhetic acid attenuates hepatic fibrogenesis in a bile duct ligation rat model. *Liver Int* 27. 548-557.2007.

- Lutchman G., Modi A., Kleiner D.E., et al:** The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. *Hepatology* 46. 424-429.2007.
- Maher J.J., McGuire R.F.:** Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo. *J Clin Invest* 86. 1641-1648. 1990.
- Mallet V.O., Dhalluin-Venier V., Verkarre V., et al:** Reversibility of cirrhosis in HIV/HBV coinfection. *Antivir Ther* 12. 279-283.2007.
- Mallette C, Flynn MA and Promrat K:** Outcome of screening for hepatitis C virus infection based on risk factors. *Am J Gastroenterol* 103. (1): 131-137.2008.
- Mandal A.K., Das S., Basu M.K., et al:** Hepatoprotective activity of liposomal flavonoid against arsenite-induced liver fibrosis. *J Pharmacol Exp Ther* 320. 994-1001.2007.
- Mangia A, Minerva N, Bacca D, et al:** Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. *Hepatology* 47. (1): 43-50. 2008.
- Manns MP, McHutchison JG, Gordon SC, et al:** Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 358. (9286): 958-965. 2001.
- Mato J.M., Camara J., Fernandez de Paz J., et al:** S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. *J Hepatol* 30. 1081-1089.1999.
- McHutchison J.G., Blatt L.M., de Medina M., et al:** Measurement of serum hyaluronic acid in patients with chronic hepatitis C

and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol 15. 945-951.2000.

McHutchison JG, Gordon SC, Schiff ER, et al: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339 (21): 1485-1492.1998.

McHutchison JG, Lawitz EJ, Shiffman ML, IDEAL Study Team, et al: Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 361. (6): 580-593.2009.

Menon D.K., Sargentoni J., Taylor-Robinson S.D., et al: Effect of functional grade and etiology on in vivo hepatic phosphorus-31 magnetic resonance spectroscopy in cirrhosis: biochemical basis of spectral appearances. Hepatology 21. (2): 417-427.1995.

Menon K.V., Stadheim L., Kamath P.S., et al: A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 99. 255-425.2004.

Metwally MA, Zein CO and Zein NN: Predictors and noninvasive identification of severe liver fibrosis in patients with chronic hepatitis C. Dig Dis Sci 52. (2): 582-588. 2007.

Mezey E., Potter J., Rennie-Tankersley L., et al: A randomized placebo controlled trial of vitamin E in alcoholic hepatitis. Hepatology 38. 264A.2003.

Miller L.C., Sharma A., McKusick A.F., et al: Synthesis of interleukin-1 beta in primary biliary cirrhosis: relationship to treatment with methotrexate or colchicine and disease progression. Hepatology 22. 518-524.1995.

- Mirella Fraquelli, Cristina Rigamonti, et al:** Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. *Gut*; 56:968-973 .2006
- Miyahara T., Schrum L., Rippe R., et al:** Peroxisome proliferator-activated receptors and hepatic stellate cell activation. *J Biol Chem* 275. 35715-35722.2000.
- Morgan T.R., Nemchausky B., Schiff E.R., et al:** Colchicine does not prolong life in patients with advanced alcoholic cirrhosis: results of a prospective, randomized, placebo-controlled trial. *Gastroenterology*. 641A.2002.
- Morra R., Munteanu M., Bedossa P., et al:** Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C. *Aliment Pharmacol Ther* 26. (6): 847-858. 2007.
- Muir A.J., Sylvestre P.B., Rockey D.C.:** Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. *J Viral Hepat* 13. 322-328.2006.
- Mulhall BP and Younossi Z:** Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. *J Clin Gastroenterol* 39: S23-S27. 2005.
- Myers R.P., Tainturier M.H., Ratziu V., et al:** Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. *J Hepatol* 39. (2): 222-230.2003.
- Nabeshima Y., Tazuma S., Kanno K., et al:** Anti-fibrogenic function of angiotensin II type 2 receptor in CCl4-induced liver fibrosis. *Biochem Biophys Res Commun* 346. 658-664.2006.
- National Institutes of Health:** National Institutes of Health Consensus Development Conference statement: management of

- hepatitis C: 2002—June 10–12, 2002. *Hepatology* 36. (5 suppl 1): S3-S20. 2002.
- Nava-Ocampo A.A., Suster S., Muriel P.:** Effect of colchicine and ursodeoxycholic acid on hepatocyte and erythrocyte membranes and liver histology in experimentally induced carbon tetrachloride cirrhosis in rats. *Eur J Clin Invest* 27. 77-84.1997.
- Naveau S., Raynard B., Ratziu V., et al:** Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. *Clin Gastroenterol Hepatol* 3. (2): 167-174.2005.
- Neal K. and Irving W.L.:** Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. *Gut* 56. (8): 1098-1104.2007.
- Nelson D.R., Tu Z., Soldevila-Pico C., et al:** Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. *Hepatology* 38. 859-868.2003.
- Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., et al:** Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. *Hepatology* 38. 1008-1017. 2003.
- Ngo Y., Munteanu M., Messous D., et al:** A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. *Clin Chem* 52. (10): 1887-1896. 2006.
- Nikolaidis N., Kountouras J., Giouleme O., et al:** Colchicine treatment of liver fibrosis. *Hepatogastroenterology* 53. 281-285.2006.
- Njoroge FG, Chen KX, Shih NY, et al.:** Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. *Acc Chem Res* 41. (1): 50-59. 2008.

- Nohlgard C., Rubio C.A., Kock Y., et al:** Liver fibrosis quantified by image analysis in methotrexate-treated patients with psoriasis. *J Am Acad Dermatol* 28. 40-45.1993.
- O'Brien M.J., Keating N.M., Elderiny S., et al:** An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C. *Am J Clin Pathol* 114. 712-718. 2000.
- O'Brien M.J., Keating N.M., Elderiny S., et al:** An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C. *Am J Clin Pathol* 114. (5): 712-718.2000.
- Olaso E and Friedman SL.** Molecular regulation of hepatic fibrogenesis. *J.Hepatol* 1998;29:836-47
- Pares A., Planas R., Torres M., et al:** Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. *J Hepatol* 28. 615-621.1998.
- Parkes J., Guha I.N., Roderick P., et al:** Performance of serum marker panels for liver fibrosis in chronic hepatitis C. *J Hepatol* 44. (3): 462-474. 2006.
- Patel K, Muir AJ and McHutchison JG:** Diagnosis and treatment of chronic hepatitis C infection. *BMJ* 332. (7548): 1013-1017.2006.
- Pilette C., Rousselet M.C., Bedossa P., et al:** Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. *J Hepatol* 28. 439-446.1998.
- Pockros P.J., Jeffers L., Afdhal N., et al:** Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of

interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. *Hepatology* 45. 569-578.2007.

Poo J.L., Feldmann G., Moreau A., et al: Early colchicine administration reduces hepatic fibrosis and portal hypertension in rats with bile duct ligation. *J Hepatol* 19. 90-94.1993.

Poon T.C., Hui A.Y., Chan H.L., et al: Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. *Clin Chem* 51. (2): 328-335.2005.

Poupon R.E., Bonnand A.M., Chretien Y., et al: Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. *Hepatology* 29. 1668-1671. 1999.

Poupon R.E., Lindor K.D., Pares A., et al: Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. *J Hepatol* 39. 12-16.2003.

Powell L.W., Kerr J.F.: Reversal of “cirrhosis” in idiopathic haemochromatosis following long-term intensive venesection therapy. *Australas Ann Med* 19. 54-57.1970.

Poynard T, Bedossa P and Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. *Lancet* 349. (9055): 825-832.1997.

Poynard T., Bedossa P., Opolon P.: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The

- OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.
Lancet 349. 825-832.1997.
- Poynard T., Imbert-Bismut F., Munteanu M., et al:** Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. *Comp Hepatol* 3. (1): 8. 2004.
- Poynard T., McHutchison J., Manns M., et al:** Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. *Gastroenterology* 122. 1303-1313.2002.
- Preaux A.M., Mallat A., Van Nhieu J.T., et al:** Matrix metalloproteinase-2 activation in human hepatic fibrosis regulation by cell-matrix interactions. *Hepatology* 30. 944-950.1999.
- Rambaldi A., Gluud C.:** Colchicine for alcoholic and non-alcoholic liver fibrosis or cirrhosis. *Liver* 21. 129-136.2001.
- Rambaldi A., Gluud C.:** Meta-analysis of propylthiouracil for alcoholic liver disease—a Cochrane Hepato-Biliary Group Review. *Liver* 21. 398-404.2001.
- Ramond M.J., Poynard T., Rueff B., et al:** A randomized trial of prednisolone in patients with severe alcoholic hepatitis. *N Engl J Med* 326. 507-512.1992.
- Ratziu V., Charlotte F., Heurtier A., et al:** Sampling variability of liver biopsy in nonalcoholic fatty liver disease. *Gastroenterology* 128. 1898-1906.2005.
- Ratziu V., Massard J., Charlotte F., et al:** Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the

- prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. *BMC Gastroenterol* 6. 66.2006.
- Regev A., Berho M., Jeffers L.J., et al:** Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. *Am J Gastroenterol* 97. 2614-2618.2002.
- Regev A., Berho M., Jeffers L.J., et al:** Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. *Am J Gastroenterol* 97. (10): 2614-2618. 2002.
- Ripoll C., Groszmann R., Garcia-Tsao G., et al:** Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. *Gastroenterology* 133. (2): 481-488.2007.
- Rockey D.C., Bissell D.M.:** Noninvasive measures of liver fibrosis. *Hepatology* 43. S113-S120.2006.
- Rockey D.C., Boyles J.K., Gabbiani G., et al:** Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture. *J Submicrosc Cytol Pathol* 24. 193-203.1992.
- Rockey D.C., Chung J.J.:** Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing. *J Clin Invest* 98. 1381-1388.1996.
- Rockey D.C., Chung J.J.:** Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis. *J Investig Med* 42. 660-670.1994.
- Rockey D.C., Maher J.J., Jarnagin W.R., et al:** Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma. *Hepatology* 16. 776-784.1992.

- Rockey D.C.:** Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol 3. 95-107.2005.
- Rockey D.C.:** Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography. Gastroenterology 134. 8-14.2008.
- Rockey D.C.:** Vascular mediators in the injured liver. Hepatology 37. 4-12. 2003.
- Rodriguez L., Cerbon-Ambriz J., Munoz M.L.:** Effects of colchicine and colchicine in a biochemical model of liver injury and fibrosis. Arch Med Res 29. 109-116.1998.
- Rodriguez-Torres M, Sulkowski MS, Chung RT, et al.:** Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. J Viral Hepat 17. (2): 139-147. 2010.
- Rojkind M., Kershenovich D.:** Effect of colchicine on collagen, albumin and transferrin synthesis by cirrhotic rat liver slices. Biochim Biophys Acta 378. 415-423.1975.
- Romero-Gomez M., Gomez-Gonzalez E., Madrazo A., et al:** Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C. Hepatology 47 (3): 810-816. 2008.
- Rosenberg W.M., Voelker M., Thiel R., et al:** Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127. (6): 1704-1713. 2004.
- Russo F.P., Alison M.R., Bigger B.W., et al:** The bone marrow functionally contributes to liver fibrosis. Gastroenterology 130. 1807-1821.2006.

- Ryder S.D., Irving W.L., Jones D.A., et al:** Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. *Gut* 53. (3): 451-455.2004.
- Ryder SD, Irving WL, Jones DA, et al.** Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. *Gut* 2004;53(3):451-5.
- Sakaida I., Tsuchiya M., Kawaguchi K., et al:** Herbal medicine Inchin-ko-to (TJ-135) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. *J Hepatol* 38. 762-769.2003.
- Sandrin L., Fourquet B., Hasquenoph J.M., et al:** Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. *Ultrasound Med Biol* 29. 1705-1713.2003.
- Sato Y., Murase K., Kato J., et al:** Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. *Nat Biotechnol* 26. 431-442.2008.
- Schaff Z., Lapis K., Szende B., et al:** The effect of D-penicillamine on CCl4-induced experimental liver cirrhosis. *Exp Pathol* 43. 111-120.1991.
- Schepke M., Werner E., Biecker E., et al:** Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. *Gastroenterology* 121. 389-395. 2001.
- Scott JD and Gretch DR:** Molecular diagnostics of hepatitis C virus infection: a systematic review. *JAMA* 297. (7): 724-732. 2007.
- Sebastiani G., Vario A., Guido M., et al:** Sequential algorithms combining non-invasive markers and biopsy for the

- assessment of liver fibrosis in chronic hepatitis B. *World J Gastroenterol* 13. (4): 525-531.2007.
- Sebastiani G., Vario A., Guido M., et al:** Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. *J Hepatol* 44. (4): 686-693.2006.
- Selman M., Carrillo G., Salas J., et al:** Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial. *Chest* 114. 507-512.1998.
- Shaheen A.A. and Myers R.P.:** Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. *Hepatology*, 2007; 46(3): 912-21.
- Shaheen A.A. and Myers R.P.:** Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection. *HIV Clin Trials* 9. (1): 43-51. 2008.
- Shaheen A.A. and Myers R.P.:** Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. *Hepatology* 46. (3): 912-921. 2007.
- Shaheen A.A., Wan A.F., Myers R.P.:** FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. *Am J Gastroenterol* 102. (11): 2589-2600. 2007.
- Shimizu I., Ma Y.R., Mizobuchi Y., et al:** Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. [see comments]*Hepatology* 29. 149-160.1999.

- Shimizu T., Kuroda T., Hata S., et al:** Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. *Kidney Int* 54. 99-109.1998.
- Siegmund S.V., Schwabe R.F.:** Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. *Am J Physiol Gastrointest Liver Physiol* 294. G357-G362. 2008.
- Siller-Lopez F., Sandoval A., Salgado S., et al:** Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. *Gastroenterology* 126. 1122-1133.2004.
- Singal A, Volk ML, Waljee A, et al:** Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. *Aliment Pharmacol Ther* 30. (1): 37-47.2009.
- Soriano V , Pouti M , Mauss M., et al:** A simple non-invasive index can predict both fibrosis and cirrhosis in HCV patients . *Hepatology* (38) 518-526.2007.
- Spahr L., Rubbia-Brandt L., Frossard J.L., et al:** Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. *J Hepatol* 37. 448-455.2002.
- Spahr L., Rubbia-Brandt L., Pugin J., et al:** Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood. *J Hepatol* 35. 582-589.2001.

- Standish R.A., Cholongitas E., Dhillon A., et al:** An appraisal of the histopathological assessment of liver fibrosis. *Gut* 55. (4): 569-578.2006.
- Stedman C.:** Herbal hepatotoxicity. *Semin Liver Dis* 22. 195-206.2002.
- Stewart S., Prince M., Bassendine M., et al:** A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. *J Hepatol* 36. (S): 16.2002.
- Stiehl A:** Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis. *Ann Med* 26. 345-349.1994.
- Strader D.B., Wright T., Thomas D.L., et al:** Diagnosis, management and treatment of hepatitis C. *Hepatology* 39. 1147-1171.2004.
- Strader DB, Wright T, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases:** Diagnosis, management, and treatment of hepatitis C. *Hepatology* 39. (4): 1147-1171.2004.
- Tada S., Nakamuta M., Enjoji M., et al:** Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. *Clin Exp Pharmacol Physiol* 28. 522-527.2001.
- Takahara T., Furui K., Funaki J., et al:** Increased expression of matrix metalloproteinase-II in experimental liver fibrosis in rats. *Hepatology* 21. 787-795.1995.
- Talwalkar J.A., Kurtz D.M., Schoenleber S.J., et al:** Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 5. (10): 1214-1220. 2007.
- Te H.S., Schiano T.D., Kuan S.F., et al:** Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. *Am J Gastroenterol* 95. 3150-3156.2000.

- Teixeira-Clerc F., Julien B., Grenard P., et al:** CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. *Nat Med* 12. 671-676.2006.
- Thampanitchawong P., Piratvisuth T.:** Liver biopsy: complications and risk factors. *World J Gastroenterol* 5. 301-304.1999.
- Thein H.H., Yi Q., Dore G.J., et al:** Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. *Hepatology* 48. (2): 418-431. 2008.
- Thompson K., Maltby J., Fallowfield J., et al:** Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. *Hepatology* 28. 1597-1606.1998.
- Tilg H., Jalan R., Kaser A., et al:** Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. *J Hepatol* 38. 419-425.2003.
- Tripathi D., Therapondos G., Lui H.F., et al:** Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis. *Am J Gastroenterol* 99. 390-394.2004.
- Tugues S., Fernandez-Varo G., Munoz-Luque J., et al:** Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. *Hepatology* 46. 1919-1926.2007.
- U.S. Preventive Services Task Force:** Screening for hepatitis C in adults, Agency for Healthcare Research and Quality Rockville, Md. November 2004. Accessed December 4, 2009.
- U.S. Public Health Service:** Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for

- postexposure prophylaxis. MMWR Recomm Rep 50. (RR-11): 1-52.2001.
- van Rooij E., Sutherland L.B., Qi X., et al:** Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316. 575-579.2007.
- Vizzutti F., Arena U., Romanelli R.G., et al:** Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 45. (5): 1290-1297.2007.
- Wai C.T., Greenson J.K., Fontana R.J., et al:** A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38. 518-526.2003.
- Wang B.E.:** Treatment of chronic liver diseases with traditional Chinese medicine. J Gastroenterol Hepatol 15. (15): E67-E70.2000.
- Wang X., Kanel G.C., DeLeve L.D.:** Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat. Hepatology 31. 428-434.2000.
- Wasley A, Grytdal S and Gallagher K:** Centers for Disease Control and Prevention: Surveillance for acute viral hepatitis—United States, 2006. MMWR SurveillSumm 57. (2): 1-24.2008.
- Wells R.G., Kruglov E., Dranoff J.A.:** Autocrine release of TGF-beta by portal fibroblasts regulates cell growth. FEBS Lett 559. 107-110.2004.
- Weng H.L., Wang B.E., Jia J.D., et al:** Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study. Clin Gastroenterol Hepatol 3. 819-828.2005.

- Westin J, Lagging LM, Spak F, et al:** Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. *J Viral Hepat* 9. (3): 235-241.2002.
- Wolfrum C., Shi S., Jayaprakash K.N., et al:** Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. *Nat Biotechnol* 25. 1149-1157.2007.
- World Health Organization:** Hepatitis C. Fact sheet N°164. Revised October 2000. Accessed March 5, 2009.
- Wright M., Thursz M., Pullen R., et al:** Quantitative versus morphological assessment of liver fibrosis: semi-quantitative scores are more robust than digital image fibrosis area estimation. *Liver Int* 23. (1): 28-34.2003.
- Wright M.C., Issa R., Smart D.E., et al:** Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. *Gastroenterology* 121. 685-698. 2001.
- Wu S.F., Peng C.T., Wu K.H., et al:** Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients. *Hemoglobin* 30. 215-218.2006.
- Yang L., Chan C.C., Kwon O.S., et al:** Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis. *Am J Physiol Gastrointest Liver Physiol* 291. G902-G911.2006.
- Yano M., Kumada H., Kage M., et al:** The long-term pathological evolution of chronic hepatitis C. *Hepatology* 23. (6): 1334-1340. 1996.
- Yata Y., Gotwals P., Koteliansky V., et al:** Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy. *Hepatology* 35. 1022-1030. 2002.

- Yates WR and Gleason O:** Hepatitis C and depression. *Depress Anxiety* 7. (4): 188-193. 1998.
- Yoneda M., Yoneda M., Fujita K., et al:** Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). *Gut* 56. (9): 1330-1331. 2007.
- Zein NN, Rakela J, Krawitt EL, et al.:** Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. *Ann Intern Med* 125. (8): 634-639.1996.
- Zeisberg M., Yang C., Martino M., et al:** Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. *J Biol Chem* 282. 23337-23347.2007.
- Zhang BH, Yang BH and Tang ZY:** Randomized controlled trial of screening for hepatocellular carcinoma. *J Cancer Res Clin Oncol* 130. (7): 417-422. 2004.
- Zhang S., Ji G., Liu J.:** Reversal of chemical-induced liver fibrosis in Wistar rats by puerarin. *J Nutr Biochem* 17. 485-491.2006.
- Zhang X.L., Liu L., Jiang H.Q.:** Salvia miltiorrhiza monomer IH764-3 induces hepatic stellate cell apoptosis via caspase-3 activation. *World J Gastroenterol* 8. 515-519.2002.
- Ziol M., Handra-Luca A., Kettaneh A., et al:** Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. *Hepatology* 41. 48-54.2005.